Aseptika Ltd began developing Activ8rlives in 2010 and is currently developing its fourth generation of integrated systems, which can be used by consumers and their healthcare service providers using a wide range of platforms or devices to better enable effective and easy self-monitoring. Incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs). Our focus is: respiratory and cardiovascular disease, cancer, promoting physical activity and weight management. Aseptika specialises in developing smart inhalers for patients with long-term respiratory conditions, which has been co-funded by the UK's Innovation Agency, Innovate UK. Aseptika third-generation smart inhaler tracker, which will have IoT connectivity built-in. This means that patients, young or old, will no longer have to send their data via a smartphone to their clinical teams, carers or parents—it will just send information over the airwaves directly to the Cloud Servers.Aseptika Limited is certified by BSI to ISO 13485:2016 under certificate number MD691414.